Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label Study to Evaluate the Safety and Efficacy of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Salvage of Treatment-Refractory Acute GVHD Patients

NCT00284986 is registered in ClinicalTrials.gov with Mesoblast, Inc. as lead sponsor.

NCT NCT00284986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00284986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label Study to Evaluate the Safety and Efficacy of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Salvage of Treatment-Refractory Acute GVHD Patients
Lead sponsor
Mesoblast, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 18, 2005
Completion date
February 8, 2007
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft versus host disease